Latest News of HYT
What are the Rangers' next steps with Filip Chytil's uncertain status?
By The New York Times |
2 days ago
The New York Rangers are facing uncertainty with Filip Chytil's injury as he undergoes evaluation after a collision. Jonny Brodzinski may fill in, with potential trade options to strengthen the team. ...
Anthony Gordon heeds England's call as no-shows undermine Lee Carsley | David Hytner
By The Guardian |
5 days ago
Newcastle winger Anthony Gordon was determined to join the England squad despite an injury, showing a positive attitude. Interim manager Lee Carsley faced numerous withdrawals before crucial matches. ...
Mikel Arteta needs 'Chelsea effect' more than ever to lift ailing Arsenal | David Hytner
By The Guardian |
1 week ago
Arsenal's manager Arteta faces a tough challenge against Chelsea, aiming to turn around their shaky form. Despite setbacks, Arteta has a strong record against Chelsea, finding success when needed most...
-
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
By Yahoo! Finance | 1 week agoTo advance a Daybreak trial population to a pivotal study, understanding genetic variants is crucial. Real-world data from French HO patients predicts positive Phase 3 outcomes. International market g...
-
Here's Why iRhythm Technologies (IRTC) Slid in Q3
By Yahoo! Finance | 2 weeks agoBaron Funds' "Baron Health Care Fund" Q3 2024 letter revealed a 5.81% gain, slightly below its benchmark. IRhythm Technologies, Inc....
-
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
By Yahoo! Finance | 3 weeks agoBoston Scientific launched the AVANT GUARD trial in 2023 to assess FARAPULSE PFA System's efficacy as a primary treatment for persistent atrial fibrillation....
-
iRhythm's Stock Skyrockets 17% After Game-Changing FDA Approval -- Is This Just the Beginning?
By Yahoo! Finance | 3 weeks agoiRhythm Technologies stock surged 17% after receiving FDA clearance for Zio AT cardiac monitoring device, addressing past setbacks and design updates. The approval enhances compliance and patient outc...
-
iRhythm secures 510(k) clearance for Zio device updates after FDA warning
By Yahoo! Finance | 3 weeks agoiRhythm Technologies received FDA clearance for design updates to its Zio AT device, a continuous monitoring system combining an ECG patch and AI-powered software. Despite previous FDA warning letters...
-
With big tests coming, Wild hope their thumpers can get into more of a 'rhythm'
By The New York Times | 4 weeks agoPaul Maurice, known for his insightful comments, discusses the Minnesota Wild's strong start and challenges. With key players like Foligno and Trenin needing to find their rhythm, Maurice and Wild coa...
-
Vinci unit Seymour Whyte secures Queensland railway upgrade contract
By Yahoo! Finance | 1 month agoSeymour Whyte, a subsidiary of Vinci Construction, in partnership with John Holland, secures a €432m contract for the Queensland railway upgrade project in Australia. The initiative aims to enhance ...
-
What we've seen and heard at Rangers camp: Shesterkin's contract, Chytil feeling good and more
By The New York Times | 1 month agoIgor Shesterkin expressed his love for the Rangers but remains uncertain about his contract extension. Talks are stalled, hinting at possible delays. Dylan Garand praises new goalie coach Jeff Malcolm...
-
Ravens weren't perfect vs. Cowboys, but they avoid 0-3 start as O-line finds its rhythm
By The New York Times | 1 month agoThe Baltimore Ravens faced a critical week of practice and preparation, focusing on improving their struggling offensive line. Coach John Harbaugh and players worked together to address challenges and...
-
Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish
By Yahoo! Finance | 1 month agoThe US Federal Reserve cutting cycle signals a new investment era amid record-high stock indices. Concerns about a slowing economy prompt interest rate cuts, impacting consumer purchasing power and va...
-
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 2 months agoRhythm Pharmaceuticals' application for expanding the use of IMCIVREE (setmelanotide) to treat children as young as 2 with Bardet-Biedl syndrome or POMC/LEPR deficiency has been accepted for priority ...
-
Rhythm Pharma Gets FDA Priority Review of Obesity Drug for Children
By MarketWatch | 2 months agoRhythm Pharmaceuticals received priority review from the FDA for its obesity treatment Imcivree for patients as young as two years old. The application targets obesity linked to specific genetic disor...